Related Experiment Video
Updated: Jun 14, 2026

Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
Published on: June 1, 2012
A dual-microneedle system for integrated continuous glucose monitoring and feedback insulin delivery
Kangxun Zhao1, Yangguang Niu1, Xiaoping Cao2
1School of Ocean Information Engineering, Jimei University, Xiamen 361021, China.
Abstract:
Effective precision diabetes management requires seamless integration of continuous glucose monitoring and therapeutic intervention. In this study, we present a novel dual-microneedle regulatory system, which combines a biosensing microneedle for real-time interstitial glucose monitoring and a therapeutic microneedle for precise transdermal insulin delivery. The biosensing microneedle utilizes glucose oxidase-functionalized electrodes for continuous glucose sensing (demonstrating a broad linear range of 1-34 mM ), while the therapeutic microneedle employs electroosmotic flow to regulate insulin infusion through hollow channels under a constant 5 V voltage. This integrated system was demonstrated to provide accurate glycemic control in diabetic Wistar rat models (achieving a 55 % blood glucose reduction within 144 min and demonstrating high clinical accuracy with 88 % of points in Zone A of the Clarke Error Grid), successfully merging continuous glucose monitoring with on-demand insulin delivery. The proposed system demonstrates a solid proof-of-concept for physically segregated closed-loop regulation, paving the way for the development of miniaturized, wearable artificial pancreas platforms for more effective diabetes management.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Drug Delivery Systems: Continuous-Release Systems
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Rate-Programmed II

